FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2081302783> ?p ?o ?g. }

• W2081302783 endingPage "3488" @default.
• W2081302783 startingPage "3484" @default.
• W2081302783 abstract "Activation of innate immunity is critical for vaccine development and immunotherapy, through triggering antigen specific immune responses. Natural killer T (NKT) cells are a unique type of innate immune cells which exert potent anti-viral and anti-metastasis function, through producing interferon-γ and activating dendritic cells to present tumor antigens to CD8 T cells. alpha-Galactosylceramide, a synthetic antigen for NKT cells, is an adjuvant for protein antigens which can induce protective immunity against cancer and viral diseases, and has been proven to be safe and immune stimulatory in human cancer and hepatitis patients. Current existing problem for alpha-galactosylceramide is its induction of anergy of NKT cells, due to the non-selective presentation of alpha-galactosylceramide antigen by B cells. We hypothesized that nanoparticle formulated alpha-galactosylceramide may be selectively presented by dendritic cells and macrophages, but not B cells, thus avoiding anergy induction in NKT cells. We have prepared poly-lactic acid based nanoparticles conjugated with alpha-galactosylceramide, examined their stimulation of NKT cells in vitro and in vivo in mice, and showed that nanoparticle formulated alpha-galactosylceramide stimulates NKT cells. In contrast to soluble alpha-galactosylceramide, which caused NKT anergy after single stimulation, nanoparticle formulated alpha-galactosylceramide repeatedly stimulates NKT cells without inducing anergy. Mechanistic studies showed that nanoparticle formulated alpha-galactosylceramide is efficiently presented by mouse CD11c + population containing dendritic cells, and CD11b + population containing macrophages, but very poorly by B220 + population containing B cells. Hence, nanoparticle formulated alpha-galactosylceramide is an attractive immunomodulator for immunotherapy and vaccine development. Future studies will be focused on its application as adjuvant for protein and/or peptide antigens." @default.
• W2081302783 created "2016-06-24" @default.
• W2081302783 creator A5007076967 @default.
• W2081302783 creator A5016553017 @default.
• W2081302783 creator A5033798832 @default.
• W2081302783 creator A5035430227 @default.
• W2081302783 creator A5043431653 @default.
• W2081302783 creator A5044032746 @default.
• W2081302783 creator A5066028652 @default.
• W2081302783 creator A5068181002 @default.
• W2081302783 creator A5085451748 @default.
• W2081302783 creator A5089378951 @default.
• W2081302783 date "2009-05-26" @default.
• W2081302783 modified "2023-10-16" @default.
• W2081302783 title "Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy" @default.
• W2081302783 cites W1943295478 @default.
• W2081302783 cites W1974227620 @default.
• W2081302783 cites W1976690411 @default.
• W2081302783 cites W1995110654 @default.
• W2081302783 cites W1997047110 @default.
• W2081302783 cites W2027947833 @default.
• W2081302783 cites W2029899137 @default.
• W2081302783 cites W2049889508 @default.
• W2081302783 cites W2086212921 @default.
• W2081302783 cites W2088064337 @default.
• W2081302783 cites W2090777237 @default.
• W2081302783 cites W2098772563 @default.
• W2081302783 cites W2114245966 @default.
• W2081302783 cites W2119695630 @default.
• W2081302783 cites W2122582242 @default.
• W2081302783 cites W2134106722 @default.
• W2081302783 cites W2142047882 @default.
• W2081302783 cites W2149389294 @default.
• W2081302783 cites W2151164793 @default.
• W2081302783 cites W2160310527 @default.
• W2081302783 cites W2161307276 @default.
• W2081302783 cites W2169141824 @default.
• W2081302783 cites W23696427 @default.
• W2081302783 doi "https://doi.org/10.1016/j.vaccine.2009.01.047" @default.
• W2081302783 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5772602" @default.
• W2081302783 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19200815" @default.
• W2081302783 hasPublicationYear "2009" @default.
• W2081302783 type Work @default.
• W2081302783 sameAs 2081302783 @default.
• W2081302783 citedByCount "70" @default.
• W2081302783 countsByYear W20813027832012 @default.
• W2081302783 countsByYear W20813027832013 @default.
• W2081302783 countsByYear W20813027832014 @default.
• W2081302783 countsByYear W20813027832015 @default.
• W2081302783 countsByYear W20813027832016 @default.
• W2081302783 countsByYear W20813027832017 @default.
• W2081302783 countsByYear W20813027832018 @default.
• W2081302783 countsByYear W20813027832019 @default.
• W2081302783 countsByYear W20813027832021 @default.
• W2081302783 countsByYear W20813027832022 @default.
• W2081302783 crossrefType "journal-article" @default.
• W2081302783 hasAuthorship W2081302783A5007076967 @default.
• W2081302783 hasAuthorship W2081302783A5016553017 @default.
• W2081302783 hasAuthorship W2081302783A5033798832 @default.
• W2081302783 hasAuthorship W2081302783A5035430227 @default.
• W2081302783 hasAuthorship W2081302783A5043431653 @default.
• W2081302783 hasAuthorship W2081302783A5044032746 @default.
• W2081302783 hasAuthorship W2081302783A5066028652 @default.
• W2081302783 hasAuthorship W2081302783A5068181002 @default.
• W2081302783 hasAuthorship W2081302783A5085451748 @default.
• W2081302783 hasAuthorship W2081302783A5089378951 @default.
• W2081302783 hasBestOaLocation W20813027832 @default.
• W2081302783 hasConcept C139563560 @default.
• W2081302783 hasConcept C147483822 @default.
• W2081302783 hasConcept C193419808 @default.
• W2081302783 hasConcept C203014093 @default.
• W2081302783 hasConcept C2776090121 @default.
• W2081302783 hasConcept C2777701055 @default.
• W2081302783 hasConcept C2778973524 @default.
• W2081302783 hasConcept C2908647359 @default.
• W2081302783 hasConcept C67662055 @default.
• W2081302783 hasConcept C71924100 @default.
• W2081302783 hasConcept C83464605 @default.
• W2081302783 hasConcept C86803240 @default.
• W2081302783 hasConcept C8891405 @default.
• W2081302783 hasConcept C99454951 @default.
• W2081302783 hasConceptScore W2081302783C139563560 @default.
• W2081302783 hasConceptScore W2081302783C147483822 @default.
• W2081302783 hasConceptScore W2081302783C193419808 @default.
• W2081302783 hasConceptScore W2081302783C203014093 @default.
• W2081302783 hasConceptScore W2081302783C2776090121 @default.
• W2081302783 hasConceptScore W2081302783C2777701055 @default.
• W2081302783 hasConceptScore W2081302783C2778973524 @default.
• W2081302783 hasConceptScore W2081302783C2908647359 @default.
• W2081302783 hasConceptScore W2081302783C67662055 @default.
• W2081302783 hasConceptScore W2081302783C71924100 @default.
• W2081302783 hasConceptScore W2081302783C83464605 @default.
• W2081302783 hasConceptScore W2081302783C86803240 @default.
• W2081302783 hasConceptScore W2081302783C8891405 @default.
• W2081302783 hasConceptScore W2081302783C99454951 @default.
• W2081302783 hasIssue "25-26" @default.
• W2081302783 hasLocation W20813027831 @default.
• W2081302783 hasLocation W20813027832 @default.

• next